摘要
肝细胞癌(hepatocellular carcinoma,HCC)是我国继肺癌之后第二大发病率与死亡率较高的慢性疾病。近年来抗肿瘤研究的焦点集中在肿瘤微环境上,其中肿瘤相关巨噬细胞(tumor-associated macrophages,TAMs)约占肿瘤浸润性炎症细胞的40%左右,在肝癌的发生、进展中发挥多重作用并与肝癌的预后呈负相关,也是近些年来抗肿瘤治疗的突破的新方向。本文从TAMs表型分化、抗肿瘤相关信号通路、免疫抑制、促血管生成、上皮细胞间质转化、介导耐药等方面进行论述,同时针对肿瘤治疗的常规疗法和新型免疫疗法进行综述。
Hepatocellular carcinoma（HCC） is the second largest morbidity and mortality rate in China after lung cancer. In recent years, tumor microenvironment has become the focus of anti-tumor research, including TAMs, and the 40% of tumor infiltrating inflammatory cells are tumor-associated macrophages（TAMs）. TAMs play multiple roles in the occurrence and progression of hepatocellular carcinoma, which is also a new direction of breakthrough in anti-tumor therapy in recent years. This article will discusses from the following aspects： TAMs phenotypic differentiation, anti-tumor-related signaling pathway, immunosuppression, angiogenesis, epithelial cell stromal transformation, mediated drug resistance, while the conventional therapy for cancer therapy and new immunotherapy will be reviewed.
出处
《生命的化学》
CAS
CSCD
2017年第6期998-1004,共7页
Chemistry of Life
关键词
肿瘤相关巨噬细胞
肝癌
信号通路
免疫
tumor-associated macrophages
hepatocellular carcinoma
signal pathway
immunotherapy
